Table 1. Summary of rebiopsy studies and the molecular and histological alterations.
Rebiopsy studies | Mechanisms of resistance to EGFR inhibitors analyzed | Histological alterations in the resistant tumor |
---|---|---|
Arcilla et al. | Pretreatment EGFR mutation: 100% | |
T790M: | ||
Standard sequencing: 49% | ||
Fragment Analysis 53% | Not performed | |
Combined standard and LNA-PCR/sequencing: 70% | ||
MET amplification: 11% | ||
Sequist et al. | Pretreatment EGFR mutation: 100% | |
T790M: 49% | SCLC transformation: 14% | |
MET amplification: 5% | ||
PIK3CA mutation: 5% | ETM: 8% | |
β-catenin mutations: 5% (all with T790M mut) | ||
Oxnard et al. | T790M: 62% | Not performed |
Ohashi et al. | B-RAF: 1% | Not performed |
SCLC, small cell lung cancer; EMT, Epithelial to mesenchymal transition